Roxatidine
As of the edition of 20 October 2026, Roxatidine is a small molecule: marketed; acts on HRH2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Altat
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- ASKA Pharmaceutical
- Registered trials
- 1, 0 stopped early
- Disease areas
- Digestive system; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Roxatidine.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HRH2 | Histamine H2 receptor | P25021 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| ASKA Pharmaceutical | Originator |